A pilot radiometabolomics integration study for the characterization of renal oncocytic neoplasia

Michail E. Klontzas, Emmanouil Koltsakis, Georgios Kalarakis, Kiril Trpkov, Thomas Papathomas, Na Sun, Axel Walch, Apostolos H. Karantanas, Antonios Tzortzakakis*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

67 Downloads (Pure)

Abstract

Differentiating benign renal oncocytic tumors and malignant renal cell carcinoma (RCC) on imaging and histopathology is a critical problem that presents an everyday clinical challenge. This manuscript aims to demonstrate a novel methodology integrating metabolomics with radiomics features (RF) to differentiate between benign oncocytic neoplasia and malignant renal tumors. For this purpose, thirty-three renal tumors (14 renal oncocytic tumors and 19 RCC) were prospectively collected and histopathologically characterised. Matrix-assisted laser desorption/ionisation mass spectrometry imaging (MALDI-MSI) was used to extract metabolomics data, while RF were extracted from CT scans of the same tumors. Statistical integration was used to generate multilevel network communities of -omics features. Metabolites and RF critical for the differentiation between the two groups (delta centrality > 0.1) were used for pathway enrichment analysis and machine learning classifier (XGboost) development. Receiver operating characteristics (ROC) curves and areas under the curve (AUC) were used to assess classifier performance. Radiometabolomics analysis demonstrated differential network node configuration between benign and malignant renal tumors. Fourteen nodes (6 RF and 8 metabolites) were crucial in distinguishing between the two groups. The combined radiometabolomics model achieved an AUC of 86.4%, whereas metabolomics-only and radiomics-only classifiers achieved AUC of 72.7% and 68.2%, respectively. Analysis of significant metabolite nodes identified three distinct tumour clusters (malignant, benign, and mixed) and differentially enriched metabolic pathways. In conclusion, radiometabolomics integration has been presented as an approach to evaluate disease entities. In our case study, the method identified RF and metabolites important in differentiating between benign oncocytic neoplasia and malignant renal tumors, highlighting pathways differentially expressed between the two groups. Key metabolites and RF identified by radiometabolomics can be used to improve the identification and differentiation between renal neoplasms.
Original languageEnglish
Article number12594
JournalScientific Reports
Volume13
Issue number1
Early online date3 Aug 2023
DOIs
Publication statusE-pub ahead of print - 3 Aug 2023

Fingerprint

Dive into the research topics of 'A pilot radiometabolomics integration study for the characterization of renal oncocytic neoplasia'. Together they form a unique fingerprint.

Cite this